Afatinib Dimaleate
(ay-FA-tih-nib dy-MAY-lee-AYT)
This page contains brief information about afatinib dimaleate and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
| US Brand Name(s): |  | Gilotrif |
| | ||
| | ||
| FDA Approved: | | Yes |
FDA Approval for Afatinib Dimaleate
Use in CancerAfatinib dimaleate is approved to treat:
- Non-small cell lung cancer that has metastasized (spread to other parts of the body). It is used as first-line treatment in patients with tumors that have certain epidermal growth factor receptor (EGFR) mutations.
Afatinib dimaleate is also being studied in the treatment of other types of cancer.
More About Afatinib DimaleateDefinition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Clinical Trials Accepting PatientsFind Clinical Trials for Afatinib Dimaleate - Check for trials from NCI's list of cancer clinical trials now accepting patients.
Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
Back to Top